Track record · closed signal

Pfizer Inc. (PFE) — closed signal from July 3, 2025

Near target Published before the outcome was known, scored automatically when the window closed on October 1, 2025 — +9.3% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$22.58 – $23.14Entry zone — fair-value band

$24.46Published — price the day we called it

$26.46Target — the price the thesis aimed for

$26.98Peak — highest point inside the window, not a realized return

$26.74Window close — end-of-window price, context only

What happened

Near target

Came within reach: 86% of the predicted growth at its peak, just short of the target.

At window close

+9.3%

realized, from the publication price to the last close inside the window

Peak gain

+10.3%

peak, from the publication price — not a realized return

S&P 500, same window

+7.2%

SPY over the identical days, dividend-adjusted

Window close

$26.74

last close inside the window, ended October 1, 2025

Peak price

$26.98

peak on October 1, 2025 — not a realized return

Days to target

—

The thesis — published July 3, 2025

Predicted growth

+12%

over the measurement window

Target price

$26.46

the price the thesis aimed for

Entry zone

$22.58 – $23.14

the fair-value band we waited for

Price at publication

$24.46

published July 3, 2025

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer offers a hefty 6.2% yearly cash payout, which many investors see as a cushion if the share price wobbles. On July 3 the US drug watchdog cleared its new RSV shot, adding fresh sales, while another heart-lung medicine is on a fast review track. After drifting for over a year the stock finally rose above its longer-term average price, hinting at improving momentum. Income hunters often move into high-dividend names before earnings, so a slide back toward the mid-$24 area could set up a three-month bounce.

Primary drivers

July 3 approval of an RSV vaccine adds a new revenue stream to Pfizer’s shot lineup.
Fast-track review for WINREVAIR may open a multi-billion lung-disease market by 2026.
A $4 billion cost-cutting plan should lift 2025 profits and free up more cash.
A 6.2% yield and shares at 10× 2025 profit lure income seekers on pullbacks.

How it played out

PFE: target was cleared by the window end

Lyra published PFE at $24.46 on July 3, with 12% expected growth and a $26.46 target. The thesis pointed to a 6.2% yearly cash payout, July 3 clearance for an RSV shot, fast review for WINREVAIR, a $4 billion cost-cutting plan, and shares at 10x 2025 profit.

Inside the July 3 to October 1 window, PFE rose to a $26.98 peak on October 1. That was above the $26.46 target, although the data did not give a day count for reaching it. The stock ended at $26.74, with a 10.3% peak gain. The thesis played out.

What happened during the window

On September 22, 2025, Pfizer announced a deal to acquire Metsera for an initial $4.9 billion, with possible additional payments tied to development milestones. On September 30, 2025, Pfizer and the U.S. government announced a drug-pricing agreement tied to Medicaid pricing, direct purchasing, and a stated $70 billion investment plan.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals